Search Results - "Buthaud, X."

Anal canal cancer treatment: practical limitations of routine prescription of concurrent chemotherapy and radiotherapy by CHAUVEINC, L, BUTHAUD, X, FALCOU, M. C, MOSSERI, V, DE LA ROCHEFORDIERE, A, PIERGA, J. Y, GIRODET, J, SALMON, R. J

“…This study is an analysis of the criteria considered when prescribing concomitant chemotherapy and radiotherapy, as a routine treatment for patients with anal…”
Get full text

State of the art and advances in radiotherapy for bladder cancer by Thariat, J, Caullery, M, Ginot, A, Hannoun-Lévi, J-M, Barrière, J, Buthaud, X, Marcié, S, Bondiau, P-Y, Housset, M, Lagrange, J-L, Amiel, J, Gérard, J-P

“…Radical cystectomy is the treatment of choice for nonmetastatic, muscle-infiltrating bladder cancer. However, bladder-sparing approaches can be discussed in…”
Get more information

OC-0434 Long -term results of OLIGOPELVIS, a Phase II Trial of pelvic RT in Oligorecurrent Prostate Cancer by Supiot, S., Vaugier, L., Pasquier, D., Buthaud, X., Magné, N., Peiffert, D., Sargos, P., Crehange, G., Pommier, P., Loos, G., Hasbini, A., Latorzeff, I., Silva, M., Denis, F., Lagrange, J., Morvan, C., Campion, L., Blanc-Lapierre, A., Paul, J.

Get full text

OC-0210: Salvage radiotherapy in oligorecurrent pelvic node relapses of prostate cancer : a phase 2 trial by Supiot, S., Pasquier, D., Buthaud, X., Magne, N., Becckendorf, V., Crehange, G., Pommier, P., Loos, G., Hasbini, A., Latorzeff, I., Silva, M., Denis, F., Campion, L., Vaugier, L., Blanc-Lapierre, A.

Get full text

Decreased topotecan platelet toxicity with successive topotecan treatment cycles in advanced ovarian cancer patients by Goldwasser, F, Buthaud, X, Gross, M, Bleuzen, P, Cvitkovic, E, Voinea, A, Jasmin, C, Romain, D, Misset, J L

“…The dose-limiting toxicities of the DNA topoisomerase I inhibitor topotecan are hematological. We prospectively analyzed the platelet toxicity pattern in…”
Get more information